4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC

Trv Gp Vi LLC acquired a new stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,211,659 shares of the company's stock, valued at approximately $141,048,460. Septerna makes up approximately 0.1% of Trv Gp Vi LLC's holdings, making the stock its largest position. Trv Gp Vi LLC owned about 9.34% of Septerna at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Deutsche Bank AG increased its position in shares of Septerna by 5.3% in the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company's stock valued at $415,000 after buying an additional 744 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Septerna during the fourth quarter valued at approximately $35,000. JPMorgan Chase & Co. boosted its holdings in Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company's stock valued at $107,000 after purchasing an additional 1,315 shares in the last quarter. PharVision Advisers LLC raised its stake in shares of Septerna by 17.5% during the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company's stock worth $224,000 after buying an additional 1,780 shares during the last quarter. Finally, Nuveen LLC boosted its position in Septerna by 7.7% during the 4th quarter. Nuveen LLC now owns 25,798 shares of the company's stock worth $719,000 after acquiring an additional 1,837 shares during the last quarter.

Septerna Price Performance

Shares of SEPN stock traded down $1.29 on Friday, hitting $39.18. The stock had a trading volume of 181,256 shares, compared to its average volume of 361,464. Septerna, Inc. has a 12-month low of $11.70 and a 12-month high of $51.10. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -72.56 and a beta of 2.29. The business has a 50 day moving average of $37.24 and a 200 day moving average of $30.75.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.14. The company had revenue of $26.75 million during the quarter, compared to analysts' expectations of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. As a group, research analysts expect that Septerna, Inc. will post -1.41 earnings per share for the current fiscal year.

Insider Activity at Septerna

In related news, insider Samira Shaikhly sold 2,178 shares of the firm's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the transaction, the insider directly owned 793 shares in the company, valued at $27,897.74. This trade represents a 73.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Elizabeth Bhatt sold 25,000 shares of the firm's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the sale, the chief operating officer owned 174,209 shares of the company's stock, valued at $7,665,196. The trade was a 12.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 61,030 shares of company stock worth $2,329,666. Company insiders own 5.80% of the company's stock.

Wall Street Analyst Weigh In

SEPN has been the subject of a number of recent analyst reports. JonesTrading upped their price target on shares of Septerna from $43.00 to $62.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Raymond James Financial reissued a "strong-buy" rating and issued a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. Wells Fargo & Company lifted their price objective on Septerna from $48.00 to $50.00 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. Truist Financial increased their price target on shares of Septerna from $35.00 to $43.00 and gave the company a "buy" rating in a research report on Wednesday, July 1st. Finally, Stifel Nicolaus set a $49.00 price objective on shares of Septerna in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $52.44.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.